Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd., commonly known as Santen, is a leading global ophthalmic pharmaceutical company headquartered in Japan. Established in 1890, Santen has a rich history of innovation in the eye care industry, focusing on the development and marketing of prescription pharmaceuticals and medical devices. With a strong presence in major operational regions including Europe, North America, and Asia, Santen is dedicated to improving the quality of life for patients with eye diseases. The company’s core product offerings include treatments for glaucoma, dry eye, and retinal diseases, distinguished by their commitment to research and development. Santen's unique approach combines advanced technology with a deep understanding of patient needs, positioning it as a trusted leader in ophthalmology. Notable achievements include a robust pipeline of innovative therapies and a strong market presence, underscoring Santen's dedication to advancing eye health globally.
DitchCarbon Score
How does Santen Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Santen Pharmaceutical's score of 46 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Santen Pharmaceutical's reported carbon emissions
In 2023, Santen Pharmaceutical Co., Ltd. reported total greenhouse gas emissions of approximately 15,296,000 kg CO2e for Scope 1 and 5,417,000 kg CO2e for Scope 2, with additional Scope 3 emissions amounting to approximately 102,440,000 kg CO2e from purchased goods and services. The company has set ambitious targets to reduce its emissions, committing to a 50% reduction in absolute Scope 1 and 2 emissions by FY 2030 from a FY 2019 baseline. Additionally, Santen aims to decrease Scope 3 emissions from purchased goods and services by 15% within the same timeframe. Santen's near-term goals include reducing Scope 1 emissions to near zero by 2025 and achieving a 30% reduction in Scope 1 and 2 emissions from 2020 levels by 2030. The company is on track to meet its Scope 2 reduction targets, which also aim for near-zero emissions by 2025. The emissions data is sourced directly from Santen Pharmaceutical Co., Ltd., with no cascading from a parent organization. The company's climate commitments align with industry standards, reflecting a proactive approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 17,021,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 19,471,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 119,598,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Santen Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
